Preview

Научно-практическая ревматология

Расширенный поиск

По материалам новых рекомендаций Европейской антиревматической лиги (EULAR) по снижению кардиоваскулярного риска у пациентов с воспалительными артритами – 2015/2016: общая характеристика и дискуссионные проблемы

https://doi.org/10.14412/1995-4484-2018-272-279

Полный текст:

Аннотация

По материалам Европейской антиревматической лиги (EULAR) в статье представлены новые рекомендации по снижению кардиоваскулярного риска у пациентов с воспалительными артритами – 2015/2016. Определены три основных принципа профилактики сердечно-сосудистых заболеваний при ревматоидном артрите и других хронических воспалительных артритах, дана общая характеристика рекомендаций с обсуждением дискуссионных проблем.

Об авторах

Т. В. Попкова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


Д. С. Новикова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
115522, Москва, Каширское шоссе, 34А


Список литературы

1. Van Halm VP, Peters MJL, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis. 2009;68:1395-400. doi: 10.1136/ard.2008.094151

2. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis. 2011;70:929-34. doi: 10.1136/ard.2010.143396

3. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-31. doi: 10.1136/ard.2009.113696

4. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-53. doi: 10.1161/CIRCULATIONAHA.107.699579

5. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. doi: 10.1016/S0195-668X(03)00114-3

6. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-81. doi: 10.1093/eurheartj/ehw106

7. Arts EE, Popa C, den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74:668-74. doi: 10.1136/annrheumdis-2013-204024

8. Gomez-Vaquero C, Corrales A, Zacarias A, et al. SCORE and REGICOR function charts underestimate the cardiovascular risk in Spanish patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15:R91. doi: 10.1186/ar4271

9. Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULARendorsed recommendations. Ann Rheum Dis. 2015;74:8-13. doi: 10.1136/annrheumdis-2014-206350

10. Dadoun S, Zeboulon-Ktorza N, Combescure C, et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine. 2013;80:29-33. doi: 10.1016/j.jbspin.2012.02.005

11. Humphreys JH, Warner A, Chipping J, et al. Mortality trends in patients with early rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register. Arthritis Care Res (Hoboken). 2014;66:1296-301. doi: 10.1002/acr.22296

12. Liao KP, Solomon DH. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). 2013;52:45-52. doi: 10.1093/rheumatology/kes243

13. Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010;69:1920-5. doi: 10.1136/ard.2009.122226

14. Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70:1921-5. doi: 10.1136/ard.2011.151191

15. Mok CC, Kwok CL, Ho LY, et al. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011;63:1182-9. doi: 10.1002/art.30277

16. Exarchou S, Lie E, Lindström U, et al. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis. 2016;75:1466-72. doi: 10.1136/annrheumdis2015-207688

17. Chou CH, Lin MC, Peng CL, et al. A nationwide populationbased retrospective cohort study: increased risk of acute coronary syndrome in patients with ankylosing spondylitis. Scand J Rheumatol. 2014;43:132-6. doi: 10.3109/03009742.2013.822097

18. Essers I, Stolwijk C, Boonen A, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Ann Rheum Dis. 2016;75:203-9. doi: 10.1136/annrheumdis-2014-206147

19. Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum. 2015;44:551-5. doi: 10.1016/j.semarthrit.2014.10.007

20. Peters MJ, Visman I, Nielen MM, et al. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis. 2010;69:579-81. doi: 10.1136/ard.2009.110593

21. Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide populationbased study. Ann Rheum Dis. 2010;69:1165-8. doi: 10.1136/ard.2009.116178

22. Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2010;37:161-6. doi: 10.3899/jrheum.090667

23. Resorlu H, Akbal A, Resorlu M, et al. Epicardial adipose tissue thickness in patients with ankylosing spondylitis. Clin Rheumatol. 2015;34:295-9. doi: 10.1007/s10067-014-2568-4

24. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore). 2009;88:358-65. doi: 10.1097/MD.0b013e3181c10773

25. Dik VK, Peters MJ, Dijkmans PA, et al. The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis. Scand J Rheumatol. 2010;39:38-41. doi: 10.3109/03009740903096101

26. Forsblad-d'Elia H, Wallberg H, Klingberg E, et al. Cardiac conduction system abnormalities in ankylosing spondylitis: a crosssectional study. BMC Musculoskelet Disord. 2013;14:237. doi: 10.1186/1471-2474-14-237

27. Horreau C, Pouplard C, Brenaut E, et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(Suppl 3):12-29. doi: 10.1111/jdv.12163

28. Buckley C, Cavill C, Taylor G, et al. Mortality in psoriatic arthritis – a single-center study from the UK. J Rheumatol. 2010;37:2141-4. doi: 10.3899/jrheum.100034

29. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326-32. doi: 10.1136/annrheumdis-2014-205675

30. Gulati AM, Semb AG, Rollefstad S, et al. On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trondelag Health Study. Ann Rheum Dis. 2016;75:819-24. doi: 10.1136/annrheumdis-2014-206824

31. Edson-Heredia E, Zhu B, Lefevre C, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol. 2015;29:955-63. doi: 10.1111/jdv.12742

32. Costa L, Caso F, D'Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31:711-5. doi: 10.1007/s10067-011-1892-1

33. Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidencebased and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72:1905-13. doi: 10.1136/annrheumdis-2013-203249

34. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896-904. doi: 10.1136/ard.2011.151027

35. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal antiinflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480-9. doi: 10.1136/annrheumdis-2014-206624

36. Del Rincon I, Battafarano DF, Restrepo JF, et al. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Ann Rheum Dis. 2014;66:264-72. doi: 10.1002/art.38210

37. Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2013. Published Online First 8 June 2013. doi: 10.1136/annrheumdis-2012-203137

38. Ajeganova S, Andersson ML, Frostegard J, et al. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J Rheumatol. 2013;40:1958- 66. doi: 10.3899/jrheum.130365

39. Arts EE, Fransen J, den Broeder AA, et al. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74:998- 1003. doi: 10.1136/annrheumdis-2013-204531

40. Myasoedova E, Chandran A, Ilhan B, et al. The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Ann Rheum Dis. 2016;75:560-5. doi: 10.1136/annrheumdis-2014-206411

41. Zhang J, Chen L, Delzell E, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73:1301-8. doi: 10.1136/annrheumdis-2013-204715

42. Barnabe C, Martin BJ, Ghali WA. Systematic review and metaanalysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63:522-9. doi: 10.1002/acr.20371

43. Chatterjee S, Sarkate P, Ghosh S, et al. Early, structured disease modifying anti-rheumatic drug (DMARD) therapy reduces cardiovascular risk in rheumatoid arthritis – a single centre study using non-biologic drugs. J Assoc Physicians India. 2013;61:531-4.

44. Desai RJ, Rao JK, Hansen RA, et al. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study. J Rheumatol. 2014;41:2129-36. doi: 10.3899/jrheum.131464

45. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108:1362-70. doi: 10.1016/j.amjcard.2011.06.054

46. Benucci M, Saviola G, Manfredi M, et al. Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. Biologics. 2013;7:69-75. doi: 10.2147/BTT.S39182

47. Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol. 2009;28:705-10. doi: 10.1007/s10067-009-1095-1

48. Kume K, Amano K, Yamada S, et al. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J Rheumatol. 2011;38:2169-71. doi: 10.3899/jrheum.110340

49. Ajeganova S, de Faire U, Jogestrand T, et al. Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis – an inception cohort study. J Rheumatol. 2012;39:1146-54. doi: 10.3899/jrheum.111334

50. Vassilopoulos D, Gravos A, Vlachopoulos C, et al. Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis. Clin Rheumatol. 2015;34:359-64. doi: 10.1007/s10067-014-2718-8

51. Vizzardi E, Cavazzana I, Sciatti E, et al. Evaluation of ascending aorta wall in rheumatoid arthritis by tissue and strain Doppler imaging during anti-tumor necrosis factor-α therapy. Clin Cardiol. 2014;37:738-43. doi: 10.1002/clc.22332

52. Mä ki-Petä jä KM, Elkhawad M, Cheriyan J, et al. Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation. 2012;126:2473-80. doi: 10.1161/CIRCULATIONAHA.112.120410

53. Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011;70:482-7. doi: 10.1136/ard.2010.135871

54. Van Sijl AM, Peters MJ, Knol DL, et al. The effect of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a metaanalysis. Semin Arthritis Rheum. 2011;41:393-400. doi: 10.1016/j.semarthrit.2011.04.003

55. Boyer JF, Bongard V, Cantagrel A, et al. Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: results from a French multicenter cohort. Arthritis Care Res (Hoboken). 2012;64:872-80. doi: 10.1002/acr.21623

56. Liao KP, Cai T, Gainer VS, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken). 2013;65:2046-50. doi: 10.1002/acr.22091

57. De Groot L, Jager NA, Westra J, et al. Does reduction of disease activity improve early markers of cardiovascular disease in newly diagnosed rheumatoid arthritis patients? Rheumatology (Oxford). 2015;54:1257-61. doi: 10.1093/rheumatology/keu459

58. Filippatos TD, Derdemezis CS, Voulgari PV, et al. Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scand J Rheumatol. 2013;42:169-75. doi: 10.3109/03009742.2012.745013

59. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of antitumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2012;64:1282-91. doi: 10.1002/acr.21693

60. Kerr G, Aujero M, Richards J, et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken). 2014;66:1619-26. doi: 10.1002/acr.22341

61. Kirkham BW, Wasko MC, Hsia EC, et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis. 2014;73:161-9. doi: 10.1136/annrheumdis-2012-202089

62. Liao KP, Playford MP, Frits M, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015;4:pii: e001588. doi: 10.1161/JAHA.114.001588

63. Navarro-Millan I, Charles-Schoeman C, Yang S, et al. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013;65:1430-8. doi: 10.1002/art.37916

64. Rho YH, Oeser A, Chung CP, et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf. 2009;2:34-40. doi: 10.1111/j.1753-5174.2009.00019.x

65. Ronda N, Greco D, Adorni M, et al. New anti-atherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arch Drug Inf. 2015;67:1155-64. doi: 10.1002/art.39039

66. McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis. 2015;74:694-702. doi: 10.1136/annrheumdis2013-204345

67. Raterman HG, Levels H, Voskuyl AE, et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis. 2013;72:560-5. doi: 10.1136/annrheumdis-2011-201228

68. Hsue PY, Scherzer R, Grunfeld C, et al. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. J Am Heart Assoc. 2014;3:e001267. doi: 10.1161/JAHA.114.001267

69. Попкова ТВ, Новикова ДС, Насонов ЕЛ. Ингибирование интерлейкина-6 и сердечно-сосудистая патология у больных ревматоидным артритом. Терапевтический архив. 2016;88(5):93-101 [Popkova TV, Novikova DS, Nasonov EL. Interleukin-6 inhibition and cardiovascular disease in patients with rheumatoid arthritis. Terapevticheskiy Arkhiv. 2016;88(5):93- 101 (In Russ.)]. doi: 10.17116/terarkh201688593-101

70. Novikova DS, Popkova TV, Lukina GV, et al. The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis. J Korean Med Sci. 2016 Feb;31(2):202-7. doi: 10.3346/jkms.2016.31.2.202

71. Navarro G, Taroumian S, Barroso N, et al. Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum. 2014;43:458-69. doi: 10.1016/j.semarthrit.2013.08.001

72. Souto A, Salgado E, Maneiro JR, et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheum. 2015;67:117-27. doi: 10.1002/art.38894

73. Strang AC, Bisoendial RJ, Kootte RS, et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. Atherosclerosis. 2013;229:174-81. doi: 10.1016/j.atherosclerosis.2013.04.031

74. Peters MJL, Voskuyl AE, Sattar N, et al. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int J Clin Pract. 2010;64:1440-3. doi: 10.1111/j.1742-1241.2009.02220.x

75. Perk J, de Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int J Behav Med. 2012;19:403-88. doi: 10.1007/s12529-012-9242-5

76. Crowson CS, Matteson EL, Roger VL, et al. Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. Am J Cardiol. 2012;110:420-4. doi: 10.1016/j.amjcard.2012.03.044

77. Arts EE, Popa CD, den Broeder AA, et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann Rheum Dis. 2016;75:674-80. doi: 10.1136/annrheumdis-2014-206879

78. Corrales A, Parra JA, Gonzalez-Juanatey C, et al. Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1764-70. doi: 10.1136/annrheumdis2013-203688

79. Hippisley-Cox J, Coupland C, Robson J, et al. Derivation, validation, and evaluation of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using QResearch database. BMJ. 2010;341:c6624. doi: 10.1136/bmj.c6624

80. Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46:2010-9. doi: 10.1002/art.10419

81. Hannawi S, Haluska B, Marwick TH, et al. Atherosclerotic disease is increased in recent-onset rheumatoid arthritis: a critical role for inflammation. Arthritis Res Ther. 2007;9:R116. doi: 10.1186/ar2323

82. Evans MR, Escalante A, Battafarano DF, et al. Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum. 2011;63:1211-20. doi: 10.1002/art.30265

83. Del Rincon I, Freeman GL, Haas RW, et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 2005;52:3413- 23. doi: 10.1002/art.21397

84. Semb AG, Rollefstad S, Provan SA, et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J Rheumatol. 2013;40:359-68. doi: 10.3899/jrheum.120621

85. Wallberg-Jonsson S, Ohman M, Rantapä ä-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol. 2004;33:373-9. doi: 10.1080/03009740410010308

86. Corrales A, Gonzalez-Juanatey C, Peiro ME, et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis. 2014;73:722-7. doi: 10.1136/annrheumdis-2012- 203101

87. Hernandez-Hernandez V, Ferraz-Amaro I, Diaz-Gonzalez F. Influence of disease activity on the physical activity of rheumatoid arthritis patients. Rheumatology (Oxford). 2014;53:722-31. doi: 10.1093/rheumatology/ket422

88. Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, et al. Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73:748- 51. doi: 10.1136/annrheumdis-2013-203291

89. Stavropoulos-Kalinoglou A, Metsios GS, Veldhuijzen van Zanten JJ, et al. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1819-25. doi: 10.1136/annrheumdis-2012-202075

90. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology. 2002;13:561-8. doi: 10.1097/00001648-200209000-00012

91. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-90. doi: 10.1056/NEJMoa1200303

92. Skö ldstam L, Hagfors L, Johansson G. An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:208-14. doi: 10.1136/ard.62.3.208

93. Baghdadi LR, Woodman RJ, Shanahan EM, et al. The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0117952. doi: 10.1371/journal.pone.0117952

94. De Vera MA, Choi H, Abrahamowicz M, et al. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2012;64:809-16. doi: 10.1002/acr.21643

95. Rollefstad S, Ikdahl E, Hisdal J, et al. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention. Ann Rheum Dis. 2015;74:1544-50. doi: 10.1136/annrheumdis-2013-204636

96. Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012;64:2836-46. doi: 10.1002/art.34524

97. Rollefstad S, Ikdahl E, Hisdal J, et al. Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases study. Ann Rheum Dis. 2015;67:1718-28. doi: 10.1002/art.39114

98. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004;363:2015-21. doi: 10.1016/S0140-6736(04)16449-0

99. Cojocaru L, Rusali AC, Suta C, et al. The role of simvastatin in the therapeutic approach of rheumatoid arthritis. Autoimmune Dis. 2013;2013:326258. doi: 10.1155/2013/326258

100. Lv S, Liu Y, Zou Z, et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. Clin Exp Rheumatol. 2015;33:69-76.

101. Cragg MS. The potential effect of statins on rituximab immunotherapy. PLoS Med. 2008;5:e77. doi: 10.1371/journal.pmed.0050077

102. Winiarska M, Bil J, Wilczek E, et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008;5:e64. doi: 10.1371/journal.pmed.0050064

103. Das S, Fernandez Matilla M, Dass S, et al. Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. Ann Rheum Dis. 2013;72:463-4. doi: 10.1136/annrheumdis-2012-202454

104. Lehane PB, Lacey S, Hessey EW, et al. Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73:1906-8. doi: 10.1136/annrheumdis2014-205474 105. Pharmacovigilance Risk Assessment Committee (PRAC). New safety advice for diclofenac – CMDh endorses PRAC recommendation. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and _events/news/2013/06/news_detail_001830.jsp&mid=WC0b01ac 058004d5c1

105. Pharmacovigilance Risk Assessment Committee (PRAC). PRAC recommends updating advice on use of high-dose ibuprofen. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and _events/news/2015/04/news_detail_002306.jsp&mid=WC0b01ac 058004d5c1

106. Van den Berg R, Baraliakos X, Braun J, et al. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford). 2012;51:1388-96. doi: 10.1093/rheumatology/kes066

107. Ajeganova S, Svensson B, Hafström I. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. BMJ Open. 2014;4:e004259. doi: 10.1136/bmjopen-2013-004259

108. Avina-Zubieta JA, Abrahamowicz M, de Vera MA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 2013;52:68-75. doi: n10.1093/rheumatology/kes353

109. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17-28. doi: 10.1136/annrheumdis-2016-209775


Для цитирования:


Попкова Т.В., Новикова Д.С. По материалам новых рекомендаций Европейской антиревматической лиги (EULAR) по снижению кардиоваскулярного риска у пациентов с воспалительными артритами – 2015/2016: общая характеристика и дискуссионные проблемы. Научно-практическая ревматология. 2018;56(3):272-279. https://doi.org/10.14412/1995-4484-2018-272-279

For citation:


Popkova T.V., Novikova D.S. ACCORDING TO THE MATERIALS OF THE 2015/2016 NEW EUROPEAN LEAGUE AGAINST RHEUMATISM (EULAR) GUIDELINES FOR REDUCING CARDIOVASCULAR RISK IN PATIENTS WITH INFLAMMATORY ARTHRITIS: GENERAL CHARACTERIZATION AND DISCUSSION PROBLEMS. Rheumatology Science and Practice. 2018;56(3):272-279. (In Russ.) https://doi.org/10.14412/1995-4484-2018-272-279

Просмотров: 241


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)